Sqz Biotechnologies Quick Ratio (SQZB) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Sqz Biotechnologies Company  (SQZB)

Sqz Biotechnologies's Quick Ratio

SQZB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2023, Quick Ratio deteriorated to 1.15 a new company low.

Within Biotechnology & Pharmaceuticals industry 148 other companies have achieved higher Quick Ratio than Sqz Biotechnologies in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 798 to 1807.

Explain Quick Ratio?
How much Cash & cash equivalents SQZB´s has?
What are SQZB´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SQZB Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change -39.65 % -44.93 % -34.48 % -6.2 % -51.07 %
Y / Y Cash & cash equivalent Change -87.9 % -76.59 % -67.56 % -55.61 % -48.71 %
Quick Ratio MRQ 1.15 2.49 3.14 2.92 5.76
SQZB's Total Ranking # 1807 # 798 # 680 # 1059 # 586
Seq. Current Liabilities Change -10.89 % -21.9 % -41.9 % 49.26 % -18.69 %
Seq. Cash & cash equivalent Change -58.75 % -38.03 % -37.42 % -24.37 % -20.2 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 149
Healthcare Sector # 727
Overall Market # 1807


Quick Ratio Statistics
High Average Low
6.35 4.46 1.15
(Mar 31 2022)   (Sep 30 2023)




Financial Statements
Sqz Biotechnologies's Current Liabilities $ 9 Millions Visit SQZB's Balance sheet
Sqz Biotechnologies's Cash & cash equivalent $ 10 Millions Visit SQZB's Balance sheet
Source of SQZB's Sales Visit SQZB's Sales by Geography


Cumulative Sqz Biotechnologies's Quick Ratio

SQZB's Quick Ratio for the trailling 12 Months

SQZB Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -29.24 % -34.76 % -36.95 % -39.06 % -44.17 %
Y / Y Cash & cash equivalent TTM Growth -69.65 % -60.37 % -52.35 % -46.05 % -37.04 %
Quick Ratio TTM 2.6 3.6 4.37 5.1 6.06
Total Ranking TTM # 3739 # 2398 # 2389 # 3649 # 3633
Seq. Current Liabilities TTM Growth -9.82 % -12.04 % -9.04 % -1.92 % -16.87 %
Seq. Cash & cash equivalent TTM Growth -34.84 % -27.56 % -22.06 % -17.49 % -14.92 %

Quick ratio ranking by company, industry and sector >> Back to SQZB Financial Strength Comparisons >> Go to Compare SQZB Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in SQZB's Current Liabilities to $8.83 millions, cumulative Quick Ratio to 2.6 below the SQZB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 171 other companies have achieved higher Quick Ratio than Sqz Biotechnologies. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2398 to 3739.

Explain Quick Ratio?
How much Cash & cash equivalents SQZB´s has?
What are SQZB´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 172
Healthcare Sector # 1041
Within the Market # 3739


trailing twelve months Quick Ratio Statistics
High Average Low
4.4 3.67 2.6
(Dec 31 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Aligos Therapeutics Inc   3.13 $ 70.429  Millions$ 22.468  Millions
Poseida Therapeutics Inc   3.10 $ 238.837  Millions$ 76.973  Millions
Relay Therapeutics Inc   2.98 $ 151.328  Millions$ 50.748  Millions
Vericel Corporation  2.93 $ 105.343  Millions$ 35.946  Millions
Exelixis Inc   2.93 $ 1,103.387  Millions$ 376.816  Millions
Inmune Bio Inc   2.91 $ 41.813  Millions$ 14.356  Millions
Armata Pharmaceuticals Inc   2.84 $ 23.958  Millions$ 8.441  Millions
Gamida Cell Ltd   2.82 $ 116.653  Millions$ 41.325  Millions
Freeline Therapeutics Holdings Plc  2.80 $ 29.452  Millions$ 10.521  Millions
Lineage Cell Therapeutics Inc   2.60 $ 41.332  Millions$ 15.881  Millions
Arcellx Inc   2.54 $ 439.716  Millions$ 173.149  Millions
Precision Biosciences Inc  2.41 $ 122.231  Millions$ 50.617  Millions
Halozyme Therapeutics Inc   2.38 $ 274.227  Millions$ 115.185  Millions
Regenxbio Inc   2.37 $ 301.887  Millions$ 127.346  Millions
Exscientia Plc  2.29 $ 185.389  Millions$ 81.047  Millions
Windtree Therapeutics Inc  2.25 $ 7.365  Millions$ 3.270  Millions
Adaptimmune Therapeutics Plc  2.15 $ 161.728  Millions$ 75.146  Millions
Immunitybio inc   2.10 $ 189.796  Millions$ 90.324  Millions
Amgen Inc   2.05 $ 34,741.000  Millions$ 16,954.000  Millions
Genfit S a   2.02 $ 87.124  Millions$ 43.098  Millions
C4 Therapeutics Inc   2.01 $ 60.971  Millions$ 30.271  Millions
Adma Biologics Inc   1.82 $ 74.157  Millions$ 40.715  Millions
Innate Pharma Sa  1.78 $ 79.078  Millions$ 44.393  Millions
Vaxart Inc   1.76 $ 19.799  Millions$ 11.268  Millions
Biomx Inc  1.76 $ 22.450  Millions$ 12.784  Millions
Moderna Inc   1.73 $ 7,573.000  Millions$ 4,385.000  Millions
Eiger Biopharmaceuticals Inc   1.69 $ 27.501  Millions$ 16.319  Millions
Neurocrine Biosciences Inc   1.58 $ 1,095.100  Millions$ 691.600  Millions
Qiagen N v   1.57 $ 1,057.782  Millions$ 672.125  Millions
Repligen Corp  1.56 $ 630.779  Millions$ 405.092  Millions

Date modified: 2026-08-31T20:16:11+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.